Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.

INTRODUCTION Non-small cell lung cancer (NSCLC) is the major cause of cancer death worldwide. Increasing evidence shows that long non coding RNAs (lncRNAs) are widely involved in the development and progression of NSCLC. lncRNA PVT1 in several cancers has been studied, its role in lung cancer remains unknown. Our studies were designed to investigate the expression, biological role and clinical significance of PVT1 in lung cancer. METHODS lncRNA PVT1 expression in 82 NSCLC tissues and 3 lung cancer cell lines was measured by quantitative Real-time PCR (qRT-PCR). Its association with overall survival of patients was analyzed by statistical analysis. RNA interference (RNAi) approaches were used to investigate the biological functions of PVT1. The effect of PVT1 on proliferation was evaluated by MTT, cell migration and invasion ability was evaluated by cell migration and invasion assays. RESULTS lncRNA PVT1 expression was significantly upregulated in NSCLC tissues and lung cancer cells when compared with corresponding adjacent normal tissues and normal bronchial epithelial cells. Increased PVT1 expression was significantly correlated with histological grade and lymph node metastasis. In addition, NSCLC patients with PVT1 higher expression have shown significantly poorer overall survival than those with lower PVT1 expression. And PVT1 expression was an independent prognostic marker of overall survival in a multivariate analysis. In vitro assays our results indicated that knockdown of PVT1 inhibited cell proliferation, migration, and invasion. CONCLUSIONS Our data indicated that lncRNA PVT1 is significantly upregulated in NSCLC tissues and may represent a new biomarker and a potential therapeutic target for NSCLC intervention.

[1]  A. Nicholson,et al.  Non-small-cell lung cancer , 2011, The Lancet.

[2]  M. Esteller Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[3]  Jin-hua Jiang,et al.  Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer , 2014, Tumor Biology.

[4]  Howard Y. Chang,et al.  Long noncoding RNAs and human disease. , 2011, Trends in cell biology.

[5]  Xing-Hua Li,et al.  Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma. , 2014, International journal of clinical and experimental pathology.

[6]  Wen-Lin Kuo,et al.  Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.

[7]  G. Lenoir,et al.  Breakpoints of burkitt's lymphoma t(8;22) translocations map within a distance of 300 kb downstream of MYC , 1994, Genes, chromosomes & cancer.

[8]  R. Spizzo,et al.  Long non-coding RNAs and cancer: a new frontier of translational research? , 2012, Oncogene.

[9]  J. Mattick,et al.  Long non-coding RNAs: insights into functions , 2009, Nature Reviews Genetics.

[10]  U. Pastorino Lung cancer screening , 2010, British Journal of Cancer.

[11]  Fang Wang,et al.  Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell‐like property of hepatocellular carcinoma cells by stabilizing NOP2 , 2014, Hepatology.

[12]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[13]  Carolyn J. Brown,et al.  The functional role of long non-coding RNA in human carcinomas , 2011, Molecular Cancer.

[14]  J. Hou,et al.  Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. , 2013, The Journal of urology.

[15]  K Sugimachi,et al.  Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers , 2013, British Journal of Cancer.

[16]  N. Caplen,et al.  p53-dependent Induction of PVT1 and miR-1204* , 2011, The Journal of Biological Chemistry.

[17]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.